Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis

NCT03915964 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03915964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03915964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
April 25, 2019
Completion date
May 28, 2025
Enrollment
2,659 (actual)
Sites
261

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis